Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.63 |
| ▸ | GSK3B | P49841 | 9/20 | 0.63 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | GSK3A | P49840 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22068721 | 0.76 | PTGS1 (0.78) | MAPK14GSK3BPTGS1PTGS2 | |
| SCHEMBL4477347 | 0.73 | MAPK14 (1.00) | MAPK14GSK3BGSK3A | |
| SCHEMBL4540895 | 0.73 | NR3C2 (0.91) | MAPK14GSK3BNR3C2 | |
| SCHEMBL20376337 | 0.71 | PTGS2 (0.58) | MAPK14GSK3BPTGS1PTGS2 | |
| SCHEMBL4559774 | 0.71 | NR3C2 (1.00) | MAPK14GSK3BNR3C2 | |
| SCHEMBL4460364 | 0.71 | MAPK14 (0.80) | MAPK14GSK3BGSK3A | |
| SCHEMBL4470597 | 0.69 | MAPK14 (1.00) | MAPK14GSK3BGSK3A | |
| SCHEMBL4460373 | 0.69 | MAPK14 (1.00) | MAPK14GSK3BGSK3A | |
| SCHEMBL4537652 | 0.69 | NR3C2 (1.00) | MAPK14GSK3BNR3C2 | |
| SCHEMBL4455399 | 0.69 | MAPK14 (0.93) | MAPK14GSK3BGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582660-B2 | 2-thio-substituted imidazole derivatives and their use in pharmaceutics | C-A-I-R BIOSCIENCES GMBH (DE) | 2009-09-01 | — | — | US | disclosed |
| US-20060235054-A1 | 2-Thio-substituted imidazole derivatives and their use in pharmaceutics | MERCKLE-GMBH (DE) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235054-A1 | 2-Thio-substituted imidazole derivatives and their use in pharmaceutics | IL2, TPMT, IFNG | MAPK14 3841/4885GSK3B 4227/4885NR3C2 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.